Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,764 total articles
nCino has shown durable booking strength and is converting growth into free cash flow. At a market cap near $1.92B and FCF of roughly $59.7M, valuation is stretched but not extreme for a SaaS fintech with improving margins. I upgrade to a buy for a position trade with an entry at $16.79, a stop at $14.30 and a primary target of $26.00 (180 trading …
EQB’s acquisition of PC Financial assets meaningfully accelerates deposit growth and lending scale. Credit-quality noise is real, but the structural benefits to funding, margin and franchise value provide a clearer path to upside. This trade idea lays out an actionable long with entry, stop and targets over a 180-trading-day horizon.
Snap’s stock popped into the $4.80s after activist noise and short-covering. Fundamentals show an $8.16B market cap, positive free cash flow, and modest valuation vs. prior highs. Against legal overhang and competition, this presents a defined-risk, high-reward swing trade opportunity.
Quanta Services (PWR) sits squarely in front of a generational U.S. reindustrialization and data center power cycle. The company’s $44B backlog, diverse end markets, and strong free cash flow profile justify a tactical upgrade. This trade idea outlines a long trade with clear entry, stop, and target while laying out the valuation framing, catalysts…
Laureate Education ($LAUR) looks like a value compounder trading at sensible multiples after a strong enrollment-driven recovery and a renewed $100M repurchase program. With a market cap near $5.05B, free cash flow of $263.1M and an EV/EBITDA of 9.8, we set a long-term trade targeting $45 while protecting capital with a $30 stop.
Achieve Life Sciences (ACHV) has been punished over the past months despite an approaching FDA review for cytisinicline. The sell-off, heavy short interest and compressed technicals have created an asymmetric risk/reward for disciplined longs who can tolerate binary regulatory risk. This trade plan defines entry, stop and target with a 180-trading-…
Nvidia's announced $2 billion investment and strategic partnership with Marvell transforms Marvell from a fast-growing networking and storage ASIC vendor into a core partner for hyperscale AI infrastructure. With data-center revenue up 21% year-over-year and management guiding revenue to roughly $11 billion, Marvell has the growth profile and cash …
Abivax (ABVX) remains a compelling long idea. Obefazimod's differentiated data package, emerging anti-fibrotic signal and concentrated asset base create strategic scarcity that magnifies upside from a successful Phase 3 maintenance readout in Q2 2026 or a takeover bid. We maintain Buy: enter at $117.65, target $150.00, stop $95.00. Trade horizon: l…
We upgrade Netflix to Buy and propose an aggressive long ahead of the next earnings print. Netflix combines strong operating margins, meaningful free cash flow ($9.46B trailing), and a growing ad business that management expects to double in 2026. At $95.32 the risk/reward favors a long exposure into earnings and the post-earnings reaction, but thi…
Meta is trading at roughly $1.47T with $46.1B in free cash flow and a PE of ~24. Management's AI product stack — from ad targeting to developer APIs and AR experiences — has near-term revenue vectors that the market is underpricing. I outline a long trade with entry, stop and target plus catalysts and risks.
Coca-Cola HBC looks set to benefit materially from a large acquisition in Africa that should expand market share, improve unit economics and lift margins. With clear operational levers and visible synergy potential, the stock offers an asymmetric risk-reward for a mid-term (45 trading days) swing trade. Entry $40.00, target $48.00, stop $36.00.
Microsoft's share price has retreated from 52-week highs while fundamentals remain robust: $2.76T market cap, $77B in free cash flow and a 30% return on equity. For value-minded investors who believe AI adoption sustains enterprise spending, MSFT is an actionable long with a clear entry, stop and upside target over the next 180 trading days.
Perpetua Resources (PPTA) is sitting at the center of two market themes - U.S. critical minerals security and renewed interest in antimony as a strategic byproduct. With the Stibnite Gold Project advancing and government capital flowing to domestic supply chains, I see a tradable upside to $36.00 from an entry at $29.00 over a mid-term horizon, whi…
Constellation Brands (STZ) looks like an actionable long after a difficult 2025 and early-2026 pullback. The business still generates strong free cash flow ($1.76B), carries a $26B market cap and a 2.95% yield, and is trading near $149. This trade targets a recovery back toward Street estimates and prior analyst targets while protecting capital wit…
IBM has pulled back from its 52-week high and is trading below several moving averages, but fundamentals remain intact: $12.1B free cash flow, a $228B market cap, and a P/E near 21.5x. Technicals show room to rebound (RSI ~44, positive MACD histogram) and strategic partnerships — including a recent security tie-up with CrowdStrike and Intel — reinf…
Marvell just secured a transformational strategic partnership with Nvidia that pairs Marvell's networking, custom processors and silicon-photonics strengths with Nvidia's AI compute scale. With data-center revenue growing 21% year-over-year and management guiding to ~40% in fiscal 2027, Marvell's growth trajectory and reasonable cash generation arg…
J.Jill (JILL) has been punished to near-term lows after weak top-line trends and margin pressure. At roughly $11.56, the shares trade below $12 with a market cap near $175M, earnings of about $2.26 per share and compelling cash flow metrics. The combination of a low P/E (~5-6), EV/EBITDA ~2.36, a dividend yield near 2.8%, and a heavily oversold tec…
Upstart is back to bargain territory: market cap around $2.5B, profitable on an EPS basis, and trading nearer its 52-week low despite solid growth and improving momentum. This trade targets a mean reversion plus re-rating over the next 45 trading days with a strict stop under the recent low.
POW (VistaShares Electrification Supercycle ETF) offers cheap, focused exposure to companies tied to the electrification value chain at $24.20. Technicals and short activity suggest a tactical re-acceleration is possible toward the 52-week high near $26.68, but macro reinflation and rotation into value could quickly compress multiples. This trade r…
Sony Group trades at $21.26 with a $127.9B market cap and a modest 2.37x book multiple after a year of sector pressure. Trailing earnings are negative, but a forward EPS of roughly $1.42 would put the stock at 15x and is well within reach if PlayStation pricing, content monetization, and imaging-semiconductor recovery normalize. We upgrade to Buy w…
adidas (ADDYY) shows signs of operational stabilization: a reasonable P/E of 18, falling short interest, improving technical momentum, and a market cap of about $28.9B that does not fully reflect the recovery in fundamentals. We upgrade to a tactical long with entry at $80.19, a stop at $76.00, and a primary target of $95.00 over a position horizon…
Nordic American Tankers (NAT) offers a compelling risk-reward for long-term investors: expanding Suezmax fleet, a recently raised dividend (30%), insider buying, and a lean float with occasional heavy short interest. Enter at $5.88, hold through 180 trading days, target $8.00 with a $4.60 stop.
Nvidia's leadership in AI datacenter GPUs, massive free cash flow and improving adoption tailwinds make the case for a multi-trillion-dollar revaluation. This trade idea outlines a long-term long position with a $400 target over ~180 trading days, a clear stop, and the catalysts and risks that could push shares toward a higher valuation.
Alcoa (AA) is benefiting from a global aluminum supply squeeze, attractive earnings and cash-flow metrics, and a modestly valued enterprise. I recommend a long trade with a $68.00 entry, $82.00 target and $60.00 stop, sized for a medium-risk portfolio and held over the next 180 trading days while catalysts play out.
Insmed's market cap sits around $35 billion while revenue expectations are still ramping. Recent FDA approval of BRINSUPRI and an advancing inhaled treprostinil program mean the company is finally building commercial scale. This trade idea bets the pipeline execution and near-term catalysts will push the stock higher, while recognizing the balance …
